Someone sent me this because many folks are trying to make comparisons. It's why message boards are so dangerous but a great place to discuss IMO. Now I repeatedly pointed out last summer that Anavex provided NO benefit for patients scoring below 20 on MMSE in their early trials and this was why their recent trial included no such patients. I also repeatedly pointed out that SAVA included all the way down to MMSE of 16 in their OLE and now also in their FDA approved trials. SAVA reported results on that 200+ patient OLE today both with mean overall scores (patients worsened as a group) as well as the prespecified subgroups of 16-20 and 21-26 (this higher group of 133 patients improved greatly). Seems to me the most beneficial comparison would be an apples to apples comparison of similar grouping of >20 MMSE scores, keeping in mind Anavex includes up to 28 which is even more mild. What doesn't seem valid would be claiming the average Anavex patients did better than the best SAVA patient on average as was portrayed in the following post. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171024028 "On average, patients, who improved cognitively with ANAVEX®2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points" Well of the small percentage of patients who apparently improved (of course a number still hidden) they improved by average of 4 points VS for SAVA "In the mild sub-group, ADAS-Cog scores improved, from 15.0 (±6.3) to 12.6 (±7.8). That's EVERY patient in the same scoring parameters of the Anavex trial (MMSE>20) which improved an average 2.4 points. Now if 10-20% (best guess based on what we know at this point) of Anavex improved an average of 4 points then the other 80-90% of the patients apparently GOT WORSE on average since PR said of "those that improved). If 100% of SAVA patients improved by an average of 2.4 points how could one make the claim that the Anavex drug is better? Surely 10-20% of Sava patients improved by an average of at least 4 points while the average of the other 80-90% IMPROVED. Just my thoughts and 6 months after completion of Anavex trial investors are still waiting to see such "mean" scores for the entire group.
How the placebo impacts this is up for debate but board readers have heard for years that placebo doesn't matter in AD right?
Market Data 
Markets 
AI
